Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Serum/Glucocorticoid-Regulated Kinase 1 (SGK1) Is a Prominent Target Gene of the Transcriptional Response to Cytokines In Multiple Myeloma and Supports the Growth of Myeloma Cells

Unn-Merete Fagerli, MD, PhD, Thorsten Stühmer, PhD, Toril Holien, Randi Utne Holt, PhD, Ove Bruland, PhD, Manik Chatterjee, MD, John Shaughnessy, Jr, PhD, Stephan Mathas, MD, Anders Sundan, MD, Ralf C Bargou, MD, Bernd Dörken, MD, Magne Borset, MD, PhD, Martin Janz, MD

Blood (2010) 116 (21): 1915.

https://doi.org/10.1182/blood.V116.21.1915.1915

Published: 2010

Journal Articles

Inhibition of the Heat Shock Transcription Factor 1 as a Potential New Therapeutic Strategy to Target Multiple Oncogenic Heat Shock Proteins in Multiple Myeloma.

Tanja Heimberger, Mindaugas Andrulis, Stephanie Fischbach, Thorsten Stühmer, Hermann Einsele, Ralf C. Bargou, Manik Chatterjee

Blood (2009) 114 (22): 2829.

https://doi.org/10.1182/blood.V114.22.2829.2829

Published: 2009

Journal Articles

Analysis of PKB/Akt-Signaling and Oncogenic Ras in Multiple Myeloma.

Torsten Steinbrunn, Thorsten Stühmer, Manik Chatterjee, Stefan Gattenlöhner, Ralf C Bargou

Blood (2009) 114 (22): 831.

https://doi.org/10.1182/blood.V114.22.831.831

Published: 2009

Journal Articles

Effects of Integrin-Linked Kinase (ILK) Inhibitor QLT0267 on Multiple Myeloma Cells and Evaluation of ILK as a Therapeutic Target in Multiple Myeloma.

Thorsten Stühmer, PhD, Torsten Steinbrunn, MD, Evelyn Grella, Ralf C. Bargou, MD PhD

Blood (2007) 110 (11): 3529.

https://doi.org/10.1182/blood.V110.11.3529.3529

Published: 2007

Journal Articles

AKT Dependent and AKT Independent Multiple Myeloma: Heterogeneity in Tumor Cell Signaling.

Angela Zöllinger, Thorsten Stühmer, Manik Chatterjee, Ralf C. Bargou

Blood (2007) 110 (11): 1511.

https://doi.org/10.1182/blood.V110.11.1511.1511

Published: 2007

Journal Articles

Signaling Profile and Anti-Tumor Activity of the Novel HSP90 Inhibitor NVP-AUY922 in Multiple Myeloma.

Thorsten Stühmer, Angela Zöllinger, Daniela Siegmund, Manik Chatterjee, Evelyn Grella, Stefan Knop, Martin Kortüm, Christian Unzicker, Michael R. Jensen, Cornelia Quadt, Patrick Chène, Joseph Schoepfer, Carlos Garcia-Echeverria, Herrmann Einsele, Harald Wajant, Ralf C. Bargou

Blood (2007) 110 (11): 4788.

https://doi.org/10.1182/blood.V110.11.4788.4788

Published: 2007

Journal Articles

Functional and Molecular Analysis of Oncogenic Pathways in Primary Myeloma Cells.

Angela Zöllinger, Thorsten Stühmer, Michael Sachs, Christian Keicher, Hermann Einsele, Ralf C. Bargou

Blood (2006) 108 (11): 5016.

https://doi.org/10.1182/blood.V108.11.5016.5016

Published: 2006

Journal Articles

Role and Regulation of Heat Shock Proteins 90alpha and 90beta in Multiple Myeloma.

Manik Chatterjee, MD, Sarika Jain, Thorsten Stühmer, PhD, Mindaugas Andrulis, MD, Ute Ungethüm, MD, Ralf-Jurgen Kuban, PhD, Kurt Bommert, PhD, Max Topp, MD, Doris Krämer, MD, Hans K. Müller-Hermelink, MD, Herrmann Einsele, MD, Greiner Axel, MD, Ralf C. Bargou, MD

Blood (2006) 108 (11): 5029.

https://doi.org/10.1182/blood.V108.11.5029.5029

Published: 2006

Journal Articles

STAT3 and MAPK signaling maintain overexpression of heat shock proteins 90α and β in multiple myeloma cells, which critically contribute to tumor-cell survival

Manik Chatterjee, Sarika Jain, Thorsten Stühmer, Mindaugas Andrulis, Ute Ungethüm, Ralf-Jürgen Kuban, Heike Lorentz, Kurt Bommert, Max Topp, Doris Krämer, Hans Konrad Müller-Hermelink, Hermann Einsele, Axel Greiner, Ralf C. Bargou

Blood (2006) 109 (2): 720–728.

https://doi.org/10.1182/blood-2006-05-024372

Published: 2006

Journal Articles

Selective Induction of the p53-Pathway as Treatment for Multiple Myeloma.

Thorsten Stühmer, Angela Zöllinger, Manik Chatterjee, Kurt Bommert, Ralf C. Bargou

Blood (2005) 106 (11): 3382.

https://doi.org/10.1182/blood.V106.11.3382.3382

Published: 2005

Journal Articles

The Y-box Binding Protein YB-1 Is Associated with Progressive Disease and Mediates Survival and Drug Resistance in Multiple Myeloma.

Manik Chatterjee, MD, Christoph Ransco, MD, Thorsten Stühmer, PhD, Niels Eckstein, PhD, Hans-Dieter Royer, PhD, Ralf Bargou, MD

Blood (2005) 106 (11): 3385.

https://doi.org/10.1182/blood.V106.11.3385.3385

Published: 2005

Journal Articles

Non-Genotoxic Targeting of p53-Dependent and p53-Independent Signaling Pathways Efficiently Kills Hodgkin/Reed-Sternberg Cells.

Martin Janz, MD, Thorsten Stühmer, PhD, Bernd Dörken, MD, Ralf Bargou, MD

Blood (2005) 106 (11): 964.

https://doi.org/10.1182/blood.V106.11.964.964

Published: 2005

Journal Articles

Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma

Thorsten Stühmer, Manik Chatterjee, Martin Hildebrandt, Pia Herrmann, Hella Gollasch, Christian Gerecke, Sebastian Theurich, Luisa Cigliano, Rudolf A. Manz, Peter T. Daniel, Kurt Bommert, Lyubomir T. Vassilev, Ralf C. Bargou

Blood (2005) 106 (10): 3609–3617.

https://doi.org/10.1182/blood-2005-04-1489

Published: 2005

Journal Articles

Combined disruption of both the MEK/ERK and the IL-6R/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells

Manik Chatterjee, Thorsten Stühmer, Pia Herrmann, Kurt Bommert, Bernd Dörken, Ralf C. Bargou

Blood (2004) 104 (12): 3712–3721.

https://doi.org/10.1182/blood-2004-04-1670

Published: 2004

NARROW

Serum/Glucocorticoid-Regulated Kinase 1 (SGK1) Is a Prominent Target Gene of the Transcriptional Response to Cytokines In Multiple Myeloma and Supports the Growth of Myeloma Cells

Inhibition of the Heat Shock Transcription Factor 1 as a Potential New Therapeutic Strategy to Target Multiple Oncogenic Heat Shock Proteins in Multiple Myeloma.

Analysis of PKB/Akt-Signaling and Oncogenic Ras in Multiple Myeloma.

Effects of Integrin-Linked Kinase (ILK) Inhibitor QLT0267 on Multiple Myeloma Cells and Evaluation of ILK as a Therapeutic Target in Multiple Myeloma.

AKT Dependent and AKT Independent Multiple Myeloma: Heterogeneity in Tumor Cell Signaling.

Signaling Profile and Anti-Tumor Activity of the Novel HSP90 Inhibitor NVP-AUY922 in Multiple Myeloma.

Functional and Molecular Analysis of Oncogenic Pathways in Primary Myeloma Cells.

Role and Regulation of Heat Shock Proteins 90alpha and 90beta in Multiple Myeloma.

STAT3 and MAPK signaling maintain overexpression of heat shock proteins 90α and β in multiple myeloma cells, which critically contribute to tumor-cell survival

Selective Induction of the p53-Pathway as Treatment for Multiple Myeloma.

The Y-box Binding Protein YB-1 Is Associated with Progressive Disease and Mediates Survival and Drug Resistance in Multiple Myeloma.

Non-Genotoxic Targeting of p53-Dependent and p53-Independent Signaling Pathways Efficiently Kills Hodgkin/Reed-Sternberg Cells.

Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma

Combined disruption of both the MEK/ERK and the IL-6R/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only